Contributing to the evolution of SCIENCE

by: Dr. Robert L. Bard

I welcome all solutionists and innovators who support the healing arts community. I have devoted my specialized work to pursue the advancement of MEDICAL RESEARCH with NON-INVASIVE SURROGATE ENDPOINTS with the hopes of contributing my talents to the performance of your current and future projects. With over 45 years in the field of advanced diagnostic science, my life's work has been about the clinical examination and targeted analyses of all subdermal disorders using the latest quantifiable digital imaging innovations. I have established an entire foundation dedicated to Medical Research committed originally to the exploratory studies of all cancer treatment proctocols. Alongside this, I have also been most active in collaboration with some of the top treatment strategists, health centers, clinical labs, experimental / alternative treatment professionals and medical device manufacturers. I have earned a reputation for my investigative approach within various examination paradigms including progress monitoring and surveillance.

As a CO-INVESTIGATOR, I have the greatest interest in supporting all entities committed to contributing technical innovations and new advancements in treatment solutions for our medical community. By this, I wish to build a partnership with establishing research teams to conduct clinical test projects where my talents to enforce validation through imaging to be a priceless benefit to your overall objectives. Most research sponsors and medical developers' testing and validation needs often fall into one of a number of common task categories- all within the objectives of public health, safety and healthcare support. I look forward to learning about your project with the hopes of supporting your needs and objectives.

Co-Investigation for CLINICAL TRIALS

Assembling top investigators and diagnosticians for research teams and studies is a major part of the end success of any medical, surgical, or behavioral intervention. This is the primary way that researchers find out if a new treatment, like a new drug or diet or a medical device is safe and effective for people. Often a clinical trial is used to learn if a new treatment is more effective and/or has less harmful side effects than the standard treatment.

Where clinical trials may test ways to find a disease or disorders early, sometimes before any apparent symptoms, others test ways to prevent a health problem. A clinical trial may also look at how to make life better for people living with a life-threatening disease or a chronic health problem. Having strong leadership at the collaborative helm of capturing and reviewing scientific data is paramount. Adding an associate investigator like Dr. Bard brings the sound advantage of experience-based perspective to any analytical or diagnostic paradigm.
(ref: https://www.nia.nih.gov/health/what-are-clinical-trials-and-studies)

It's all about PATIENT PROGRESS
Medical research protects the relationship between the developer of clinical solutions and the patient community of its treatment or performance claims. Tests performed by an unbiased agencies like the AngioFoundation ensures the acquisition of untainted, unbiased data from a dedicated review campaign.
Who needs CLINICAL TRIALS?
Medical device manufacturers/inventors, drug developers, producers of additives and supplements or any entities that create materials that are accessory to healthcare treatments. Also, upgrades and modifications to these products will require further PROOFING or VALIDATION under similar testing.
Uses for ACQUIRED DATA
Producers earn the benefits of public confidence from the information harvested in Clinical Trials. To establish performance standards (let it be through regulatory compliance testing or internal quality assurance reviews) is a significant asset for any product being introduced into the market.

From Local to Global:
ENTER THE AGE OF REMOTE MEDICAL ACCESS

The subdermal ultrasonic technology has become a powerful new standard in diagnosing and treating patients. The movement to "go digital' also brings significant advantages between clinicians in different locations by allowing them to share patient scans and test images in real time. This benefit is also greatly used in clinical trials from multiple locations. Working with a team is no longer limited to localized personnel; today's medical project allows complete working access to the most credentialed experts from any part of the globe. Dr. Bard has proven this work paradigm throughout his career -having partnered with countless clinical teams and research groups in European medical centers who sought his specific experience and diagnostic talents. Thanks to the use of the latest CLOUD-BASED imaging programs, trial projects can easily acquire, host, transfer and securely deliver any and all 3D/4D subdermal imaging of a patient (or test case) via REMOTE ACCESS. This innovation significantly adds a new level of efficiency and performance to any research project while greatly reducing trial costs and delays.

Advantages of Diagnostic Imaging in RESEARCH STUDIES

CLINICAL TRIALS: TREATMENT PROGRESS TRACKING
Use of Advanced Digital (3D/4D) Doppler Sonographic Imaging technology to MONITOR, TRACK, SCREEN and IDENTIFY all treatment responses, successes & efficacy. The AngioFoundation team is experienced with designing a comprehensive Clinical Trial format for all medical protocol developers. The Doppler system is the safest repeat scanning solution for performance monitoring and staging use (no radiation) allowing the tester to accurately achieve and generate a comparative view of Before-After studies. Working with all test patients within this proven and stable paradigm can be incorporated with other current imaging technologies such as MRI, CT etc. Acquire useful data from concurrent patient testing programs such as: duration of desired response, resistance analysis, dosage-effect ratios, statistics assessment, secondary physiological responses and more.

VALIDATION REPORTING FOR INSTITUTIONAL STANDARDS & COMPLIANCE
Dr. Bard has supported countless projects, many of them pertaining to the achievement of regulatory standards. From medical device companies, clinical labs and pharma products, our resarch programs have helped to achieve proper certifications and compliance. By this, we perform a complete and highly detailed VALIDATION analysis of the product in question- reviewing all available benefits, a comprehensive assessment of their intended usage and short and long term effects- detailed within your compliance applications, supportive documentation and ansilary reporting.

CUSTOMIZED DESIGNS OF RESEARCH STUDIES
As a researcher, Dr. Bard welcomes collaborating with all developers under varying types of research paradigms. To determine a conclusive study within sensible variable scenarios or to help identify and confirm the developer's intended results of their product design, we can offer a wide array of clincal trial design angles including: CASE-CONTROL STUDIES, CASE REPORTING, META ANALYSES, COST-BENEFIT ANALYSIS, DOUBLE BLIND STUDIES, EMPIRICAL RESEARCH just to name a few.
DEDICATED MONITORING OF PRE AND POST-TREATMENT PROGRESS
Within a closed testing program of 45-50 patients, a comparative review of pre and post treatment allows the developer a clear view of its efficacy and performance. Through the use of various imaging technologies and the experienced assessment strategies of our diagnosticians, we are able to provide the desired data which leads the devleoper to identify quality standards as they apply to the inevitable end user en masse.


Research & Educational PROGRAMS
The AngioFoundation has been recognized worldwide by official medical organizations and peer reviews for its work in FIVE MAIN focal topics and class divisions. We continually maintain and update research works in these categories to support the advancement of these disciplines as part of The AngioFoundation's commitment to the scientific community. Below is a selected examples of medical reseearch projects:

• Efficacy of Injected Hyaluronidase Filler Reduction Dept Dermatology Mt Sinai
Marmur E  HS#14-00291 | Icahn School of Medicine 2015

• Photoacoustic and Optical Imaging
Bard R, Krueger L, Rasmussen S Rockefeller University 2013-2014

• Doppler Evaluation of Radiation Treatment Response
Bard R, Kaplan A 2013-2014 NY Medical College

• 3D Doppler Sonography of Malignant Melanoma 
Bard R, Lefkovitz A In conjunction with Mt Sinai Medical Center New York, NY 2013-2014

• 3D Imaging of Psoriasis
Bard R, Lebwohl M, Wortsman X In conjunction with Mt. Sinai Med Ctr New York, NY 2012

• Doppler Vessel Density in Melanoma
Morton D, Bard R in conjunction with John Wayne Cancer Institute Santa Monica 2009-2010

•  Prostatic Volume Reduction Implementing Radiotherapy Treatment Application
Rotman M, Bard R.  Applications in Prostate Cancer Patients 2006-2008
In conjunction with Downstate Medical Center Brooklyn, NY

• Ultrasonography of the Spine in Rheumatoid Arthritis
Smith M, Bard R | Dept Rheumatology St. Vincents Hospital New York 2000-2001
in conjunction with New York Medical College Valhalla, NY

• Ultrasound Evaluation of the Patient with Rheumatoid Arthritis
Smith M, Prashad R, Bard R et al | Dept Rheumatology St. Vincents Hospital New York 1997-1998 in conjunction with New York Medical College Valhalla, NY

Click HERE at pgs 19-21 for a complete list of AngioFoundation Research Projects

 

Scientific PUBLICATIONS
A significant asset to the medical community is publishing our research studies for complete academic access through medical journals and through full-text distribution with Springer Publishing Inc. Publishing all findings of our research reports maintains the tradition of supporting the growth of current and future generations of clinicians and for the expansion of the vast majority of relevant audiences who benefit from our discoveries. Under the authorship of Dr. Robert Bard, we have amassed over 18 combined years of research and generated countless articles, over 22 scientific textbooks with various topics and hundreds of presentations to the medical community worldwide.

(see Pg. 6-19 books published & international presentations)


Recent & Innovative PROJECTS
Within the past decade, the world of medicine has witnessed (and achieved) a significant amount of success with STEM CELL therapies managing a wide range of disorders. There are 2 main types of stem cell transplant processes- AUTOLOGOUS (source of harvested cells are the same as the recipient) and ALLOGENIC (sourced from a matching donor). Concentrates of regenerative cells can be extracted from bone marrow, unbillical cord (newborns) or fat (adipose) cells & bloodstream. Patients are (now) recognized to receive treatments for a growing list of isses such as ORTHOPEDIC damage (bone and joint injuries) and AUTO-IMMUME DISORDERS (lupus, arthritis, diabetes ). NEUROLOGICAL ISSUES are also now being addressed by stem cell treatments whereby research and testing for treatment efficacy relating to the Nervous System is also in full swing within the clinical community.

Dr. Bard's 4D Doppler capabilities have become the preferred non-invasive solution with research programs to seek out treatment validations or application performance tracking for this exact type of exploratory testing. Dr. Bard has the capacity to identify and track prestroke vasospasms, any increase in intracranial pressure, brain aneurysms and many degenerative disorders. (See related article)


Early collaboration with technological FRONTIERSHIP

In 1976, during Dr. Bard's days as a young radiologist, he was approached by Dr. Henry Leis Jr., the pioneer doctor who wrote the very first text on breast cancer and developed mammography 18- a means of early diagnosis and instrumental in the use of many of the less invasive procedures used in the treatment of breast cancer today. He confessed with great concern that he had all these patients with lumpy or cystic breasts developing tumors that he could clearly feel but the mammogram kept missing it. Seeking Dr. Bard's help through sonogram technology, they worked on his patients together and the sonogram clearly identified and quickly diagnosed a mass as either a cancer or a benign cyst, in a dense, lumpy breast. Since then, the sonogram became incorporated in high-risk patients’ regimen every six months religiously because it finds tumors while they're small and “lumpectomy” surgery is curative if the mass is less than 1 cm. This is alongside doing mammograms once a year in women over 50 or unless they have a history of cancer- at which case, we do it starting at age 45.

 

Why go DOPPLER?

There are other ways of looking at blood flow in tumors. CAT scans and CT radiation imaging was spectacular at finding breast cancer except the radiation dose was so high that patients were developing lung cancer from it. Also, claustrophobic people couldn't fit into the CT or the MRI tube. MRI also uses the blood flow technology but some people are allergic to the contrast from the CT or the MRI. We also learned that the MRI contrast is depositing now in the brain, causing other problems that we're just being aware of. The Doppler Sonogram is technically instantaneous. You put the probe on the specific area of the body, find the area of interest, pinpoint it, press a button and seconds later you have the map showing the types of tumor(s) from various vantage points. You have a program on the computer to give you the vessel density measurement which shows how aggressive this is. Instead of the genetic markers, which are very popular, showing how aggressive a tumor will be, this is a visual way in seconds that's being used worldwide to show cancer vessel aggression. Tumor aggression by blood flow evaluation is used worldwide in nuclear medicine, CT scans and MRI technology-- however, the simplest and most efficient way to get real-time response is through the non‐invasive 3D Doppler procedure.

 

 

Research Support and Fundraising EVENTS

May 10, 2018- NYC; The LOTOS CLUB hosted the 2018 speaker series with Dr. Robert Bard's opening presentation on Early Detection & Prevention by NYCRA (New York Cancer Resource Alliance) and endorsed Dr. Bard to launch this theme because of his expanded knowledge in today's modern diagnostic technologies and non-invasive applications including the 4D Doppler ultrasound technology - much of which has been driven by European medical influence for the cancer treatment community. Dr. Bard is an internationally recognized leading expert in the use of this process for the screening, scanning and pre/post procedural monitoring of Breast, Prostate & Skin Cancers. He is also known for his public mission to replace surgical analysis of tumors with his coined "digital biopsies". Dr. Bard gave the standing-room only audience at the LOTOS CLUB an astounding look at the effectiveness of his imaging process to the surgical chain. He shared images of actual patient cases including the study of blood flow in tumors, behaviors of cysts, foreign bodies in trauma cases, fracture analysis and proven ways that cancers can be safely detected, studied and even treated with the use of non-surgical means. The high accuracy of 3D-4D Histogram analysis allows cancer treatment to be implemented without invasive biopsies that may spread tumor cells. (full article)

 

 

Research results in APPLIED SCIENCE

IMAGING ASSISTS SURGICAL PLANNING OF INDICATED BIOPSIES

In my extensive career as the medical director of an advanced imaging diagnostics practice, I have provided great assistance to many surgeons with my work using advanced Doppler Scanning of Tumors and Cosmetic Disorders. I have uncovered countless dermal and subcutaneous issues that would have otherwise gone undetected with less effective technologies, leading to potential complications in the surgical procedure and patient recovery. The advancement in this innovation empowers upcoming surgical procedures with remarkable confidence of a safer end result. Where biopsies are becoming a thing of the past, our non-invasive 4D Digital imaging replaces weeks of lab work and radiologic tests and often provides more useful information. (see complete article)

 

DIGITAL BIOPSY CASES: WHAT ARE YOU ABOUT TO BIOPSY? WHAT HAPPENS AFTER THE NEEDLE INSERTS? Here we have 2 subdermal masses which are non tender and firm with no history of trauma. Case A: The oval mass (dark echoes=suspicious) with irregular vessels (red) was referred as a probable cyst or lipoma. The tumor is highly vascular and connected from the aorta by way of the subclavian feeding artery. Liposuction could result in massive hemorrhage and spread of tumor cells into the circulation.

 

Case B: The ovoid white region (bright echoes=benign) is ossified as confirmed by the CT scan of the coccyx. The sonogram allows you to reassure the patient it is NOT CANCER. It prompts one to avoid a standard needle that could bend, crack or dislodge into the soft tissues requiring further exploration to locate/retrieve the broken metal fragment.

  FOR MORE DETAILS PLEASE CONTACT US DIRECTLY AT OUR MAIN OFFICE: 212.355.7017
Copyright (C) 2019- BardPublications Inc. & BardClinicalTrials.com. All Rights Reserved.